Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AFT Pharmaceuticals Ltd. ( (NZ:AFT) ) has provided an update.
AFT Pharmaceuticals, a New Zealand-based multinational drug maker with a broad mix of proprietary and in-licensed products sold through OTC, prescription and hospital channels, is expanding globally by developing and in-licensing medicines for core markets and out-licensing them to distributors in over 125 countries. The company said it will release its full-year FY2026 results for the year ended March 31 on May 21, with management to host a webcast presentation shortly after, signaling an upcoming update on its financial performance and operational progress for investors and other stakeholders.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across multiple therapeutic categories. Its products span over-the-counter, prescription and hospital channels, including patented, branded and generic drugs, with a business model focused on developing and in-licensing products for key markets and out-licensing them to partners in more than 125 countries.
See more insights into AFT stock on TipRanks’ Stock Analysis page.